The PI3K Pathway in Human Disease Review uri icon


MeSH Major

  • Phosphatidylinositol 3-Kinases
  • Signal Transduction


  • Phosphoinositide 3-kinase (PI3K) activity is stimulated by diverse oncogenes and growth factor receptors, and elevated PI3K signaling is considered a hallmark of cancer. Many PI3K pathway-targeted therapies have been tested in oncology trials, resulting in regulatory approval of one isoform-selective inhibitor (idelalisib) for treatment of certain blood cancers and a variety of other agents at different stages of development. In parallel to PI3K research by cancer biologists, investigations in other fields have uncovered exciting and often unpredicted roles for PI3K catalytic and regulatory subunits in normal cell function and in disease. Many of these functions impinge upon oncology by influencing the efficacy and toxicity of PI3K-targeted therapies. Here we provide a perspective on the roles of class I PI3Ks in the regulation of cellular metabolism and in immune system functions, two topics closely intertwined with cancer biology. We also discuss recent progress developing PI3K-targeted therapies for treatment of cancer and other diseases.

publication date

  • August 10, 2017



  • Review



  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.cell.2017.07.029

PubMed ID

  • 28802037

Additional Document Info

start page

  • 605

end page

  • 635


  • 170


  • 4